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Background: Orofacial pain (OFP) is an undesirable sensation frequently associated with head and neck cancer 
(HNC) and its treatment. OFP negatively impacts the quality of life of oncological patients. The approach to OFP 
diagnosis and management can differ if the patient visits a dentist or physician. The aim of this study was to present 
a case series of HNC with OFP managed by a dentist team and to discuss its role in the management of OFP. 
Material and Methods: We recruited twenty-two adult patients with OFP and previous diagnosis of HNC referred 
to an academic dental clinic from 2015 to 2017.
Results: Nociceptive was more frequent than mixed and neuropathic pain, however 54,4% of the cases showed a 
neurological component. All types of pain were managed by dentist through removal of pain’s cause and appro-
priated local and systemic treatment. The intensity of pain was reduced in 86,3% of patients, and 45,4% of them 
reported absence of pain at the end of treatment. 
Conclusions: Dentist’s assessment plays a distinct and crucial role in the diagnosis and management of OFP in 
HNC patients throughout the oncological treatment.
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Introduction
Head and neck cancer (HNC) are a group of malignant 
neoplasms that arises in the oral cavity (40%), oro-
pharynx and hypopharynx (15%), and larynx (25%) 
(1). Orofacial pain (OFP) is reported by approximate-
ly half of HNC patients prior to oncology therapy, 81% 
during treatment, 70% at the end of therapy and 36% 
six months after treatment (2). Ideally physicians and 
dentists should work in collaboration to obtain a precise 
diagnosis and determine the best approach to OFP. The 
management plan may be different depending on which 
specialist the patients seeks for consultation, becau-
se the pain could involve dental diseases, neurological 
problems, co-morbidities, depression and other forms of 
chronic pain. Moreover, a biopsychosocial approach is 
advised to achieve a treatment (3).
According to the National Institute of Health (2016) 
“pain is an undesirable sensation of discomfort, an 
unpleasant human experience that decreases the quali-
ty of life in patients with cancer” (4). Therefore, pain 
negatively affects cancer patients and their relatives (5). 
Cancer-induced pain may be due to nociceptive, neuro-
pathic or mixed mechanisms. Nociceptive pain is related 
to involvement of specific structures like bone, muscle 
or viscera. Neuropathic pain is due to involvement of 
peripheral or central afferent neural pathways. Mixed 
mechanisms present more than one element of the noci-
ceptive and neuropathic features (6). 
OFP may be caused by direct cancer involvement of 
anatomical structures, toxicity of oncological treat-
ment or patient comorbidities (2, 3). In the oral cavi-
ty, overlooked dental and periodontal disorders prior 
to cancer therapy are the commonest acute causes of 
OFP in HNC patients (7). Oral mucositis and stomatitis 
are also a frequent acute adverse effect of combined 
chemotherapy and radiotherapy (CRT). In this context, 
the incidence of severe mucositis ranges between 60% 
and 90%, which significantly increases pain during 
anti-cancer treatment (8). Temporomandibular disor-
ders (TMD) cause musculoskeletal pain and frequently 
affect HNC patient. Trismus is a TMD resulted from 
damage of the masticatory muscles, a late complica-
tion of head and neck radiotherapy (9). Burning mouth 
syndrome (BMS) and painful post-traumatic trigeminal 
neuropathy, chronic neuropathic conditions characteri-
zed by unilateral or bilateral facial or burning oral pain 
of the tongue and other parts of the oral mucosa, could 
be secondary to nerve damage induced by CRT (10). 
Detection and proper management of those oral disor-
ders requires a dental specialist with experience in the 
management of oncological patients. 
Preventive measures and effective analgesia are the ba-
sis of multidisciplinary cancer pain management (2,3). 
The ability to provide an efficient treatment depends on 
meticulous clinical exam, knowledge of pharmacologi-
cal and non-pharmacological agents and recognition of 
pain episodes (7).
This study aimed to report our experience in the diagno-
sis and management of OFP in HNC patients referred to 
an academic dental outpatient clinic and to discuss the 
importance of a dentist in the multidisciplinary approach 
to oncological patients with OFP.
Material and Methods
This study was approved by the Institutional Ethics and 
Research Committee (protocol number 904.529). We 
recruited adult patients with OFP and previous diagno-
sis of HNC referred to an academic dental clinic from 
March 2015 to November 2017. Eligible patients that 
accepted to participate and provided an informed con-
sent entered the study. 
-Dentist’s structured interview 
Clinical examination started with a structured interview 
to assess demographic data; type, localization and sta-
ge of HNC; timing of oral assistance (before, during, or 
after oncological treatment); modality (surgery, chemo-
therapy, and radiotherapy) and duration of oncological 
therapy; smoking and alcohol abuse; and co-morbidities.
The OFP history included the following data: location 
and radiation (dental, mouth mucosa, musculoskeletal, 
and neurological);  timing (onset, duration, and periodi-
city); quality (LANSS - Leeds assessment of neuropa-
thic symptoms and signs – scale part A) (11); intensity 
(VAS - visual analog scale) (12); modifying factors of 
pain (relieving and aggravating factors); and previous 
attempts of pain management. 
Patients with HNC rated pain intensity, according to a 
validated VAS (12). The use of 0 to 100 mm VAS scale 
was explained for patient self-assessment (12, 13). The 
wording used for pain intensity assessment was “no 
pain” and “worst pain imaginable”. We described their 
pain intensity based in cut-off points on VAS: no pain 
(0–4 mm), mild pain (5–44 mm), moderate pain (45–74 
mm), and severe pain (75–100 mm) (14). Pain intensity 
was measured in each consult and recorded for compa-
rative analysis in the first (VAS1) and last dental query 
(VAS2). 
-Oral and maxillofacial examination
A dentist with expertise in orofacial pain realized a 
complete face, head, neck, and oral cavity examination 
by inspection, palpation, percussion, and auscultation. 
Mandibular active range of motion, standardized tempo-
romandibular joint, masticatory and cervical muscle pal-
pation were also done, according to research diagnostic 
criteria for temporomandibular disorders (RDC/DTM) 
(15). For nociceptive or neuropathic pain differentiation 
LANSS scale part B was used (11).
Dental and periodontal examination was done by a com-
bination of clinical and radiographic analysis. Cold sti-
muli to the clinical crown by Endo Ice spray was done 
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when caries, restorations (defective, newly placed) or 
tooth pain history was present. Periodontal status was 
defined after probing and dental mobility analysis.
-Dentist diagnosis and management
The types of dental treatment protocols were categori-
zed according to anti-cancer therapy timing (16-18). For 
patients with dental pain diagnosed before oncological 
treatment and without time constraint or systemic limi-
tations, a complete protocol was indicated. This protocol 
included: 1. Repair of all teeth with caries; 2. Extraction 
of teeth with severe caries, apical periodontitis, advan-
ced periodontal disease (probing depth ≥ 6 mm and/or 
furcation I, II, III), mobile primary teeth (>50% root 
resorption), and partially erupted third molars. Partial 
protocol was the best option for patients with time cons-
traint or systemic limitations and dental pain diagnosed 
before CRT. This protocol differed from complete pro-
tocol in that: 1. mild/ moderate caries were restored de-
pending on time availability; 2. Extraction of teeth with 
severe caries, apical periodontitis (symptomatic lesion 
and lesions ≥ 5 mm), advanced periodontal disease (pro-
bing depth ≥ 8 mm, mobility III, severe inflammation), 
severe mobility, and partially erupted third molars with 
purulent secretions of pericoronitis. Intervention only in 
dental pain was the option for patients that did not have 
time or systemic conditions to complete or partial dental 
treatment and for patients during CRT. For patients who 
manifest severe dental pain or give a previous history of 
pain in teeth with symptoms of mild or moderate pain 
and had not systemic problems, extraction was indica-
ted. Another dental pathology, if present, was monitored 
during anti-neoplastic therapy.
The complete dental treatment protocol was also the op-
tion for patients after CRT. For patients with indication 
of tooth extraction in the field of radiation were pres-
cribed the osteonecrosis prevention protocol which in-
cluded amoxicillin (2 g) or clindamycin (600 mg) taken 
orally one hour before the surgery and half of dose every 
eight hours for seven days after extraction; and antibac-
terial mouthwashes with 10 ml of chlorhexidine gluco-
nate 0.12% solution for one minute twice a day starting 
seven days before extraction and continued for seven 
days after extraction (17,18). 
Severity of oral mucositis was defined by World Health 
Organization (WHO) (8) as Grade 0: none on oral mu-
cosa; Grade 1: erythema and soreness, no ulcer; Grade 
2: oral erythema, ulcers, solid diet tolerated; Grade 3: 
oral ulcers, liquid diet only; Grade 4: unable to tolerate a 
solid or liquid diet. Among the few mucositis prevention 
and treatment measures available, photobiomodulation 
(PBM) with low-level laser therapy (LLLT) was applied 
(19). The PBM protocol for treatment of oral mucositis 
was 660 and 808 nm, 100mW, 2J/cm2 on the lesions, 
once a week. 
TMD was managed through thermotherapy (10 minutes 
of warm water compression at the pain site, three times 
a day) (20), oral muscle relaxant agents and adjuvants, 
and systemic analgesics as needed according to WHO 
analgesic ladder (21,22). 
Diagnostic anesthetic blocks (23) were useful in loca-
lizing symptoms in some cases of neurophatic pain. 
Pharmacological management of neurophatic pain fo-
llowed WHO analgesic ladder (21). Anticonvulsants 
(carbamazepine, gabapentin), antidepressants, and other 




Twenty-two patients (eighteen male/four female) agreed 
to participate in the study (Table 1, 1 continue, 1 con-
tinue-1). Mean age was fifty years (range: eighteen to 
seventy-three years-old). Twenty-one patients had SCC 
(squamous cell carcinoma) and one patient had cervi-
cal Hodgkin’s lymphoma. The primary neoplasm was 
in advanced stage and their locations were: oropharynx 
(22,7%); tongue (22,7%); larynx (13,6%), maxillary si-
nus (9%); amygdala (9%); parapharynx space (4,5%); 
mandible (4,5%); cheek (4,5%); mouth floor (4,5%) and 
cervical lymph node (4,5%). Thirteen patients (59%) 
had undergone cancer therapy previously. Four patients 
(18,1%) were still undergoing oncological treatment at 
the first dental consultation. Five patients (22,7%) had 
not started cancer therapy before referral to our dental 
clinic. Eighteen patients (81,8%) received CRT during 
one to eight months, and ten (45,4%) also underwent 
surgical resection. 
The majority of patients reported alcohol (86,3%) and 
tobacco (90,9%) consumption. Ten patients (45,4%) 
interrupted this consumption after malignancy diag-
nosis. Nine patients (40,9%) presented co-morbidities: 
arterial hypertension (18,1%), urinary tract infection 
(4,5%), hypothyroidism (4,5%), diabetes mellitus type 
II (4,5%), depression (4,5%), gallbladder stones (4,5%) 
and gastritis (4,5%). 
-Pain diagnosis and management
OFP was associated with more than one diagnosis in 
50% of the patients. The etiologies included: neurolo-
gical (54,5%), musculoskeletal (50%), pulpitis (45,4%), 
periodontitis (18,1%), mucositis (9%) and bite in oral 
mucosa (4,5%). The most frequent type of pain was 
nociceptive (45,4%), followed by mixed type (36,3%) 
and neuropathic pain (18,1%). Eight patients (36,3%) 
reported continuous pain. In all other patients, pain was 
intermittent (63,6%) though lasting for more than two 
hours. Ten patients (45,5%) reported severe pain accor-
ding to VAS. Five patients (22,7%) referred moderate 
pain and seven (31,8%) reported mild pain. Twenty pa-
tients (90,9%) reported a specific type of pain sensation: 
stinging (36,3%), throbbing (27,2%), pressure (18,1%), 
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burning (18,1%), needle prick (9%), tingling (4,5%) and 
painful cold sensation (4,5%). Four patients (18,1%) 
complained simultaneously by two or more pain sensa-
tions. 
Two patients (9%) reported spontaneous pain. The 
others (90,9%) had at least one pain trigger or aggra-
vating factors: chew (59%) of fibrous food (36,3%); ice 
(50%), hot (36,3%), seasoned (22,7%) or sweet (22,7) 
food intake; open mouth movement (22,7%); stress 
and anxiety (18,1%); touch (13,6%); dental overload 
(13,6%); toothbrush (4,5%); decubitus (4,5%) and mou-
th breath (4,5%). Eighteen patients (81,8%) reported 
pain relief measures. Drugs were the most cited, inclu-
ding: standard oral analgesic (63,6%), opioids (45,4%), 
nonsteroidal anti-inflammatory drugs (13,6%), anticon-
vulsants (9%), oral corticoids (4,5%) and warm liquids 
(4,5%). Ten patients (45,4%) used a combination of two 
or more drugs. 
OFP in 50% of the patients arose in dental structures due 
to pulpitis and periodontitis. In this group, exodontia 
was indicated in ten patients (45,4%), and one patient 
also underwent PBM (5J/cm2) once a week in all teeth 
because of dental sensibility. One patient was managed 
with fluoride therapy for white spot lesion in all teeth 
with sensibility and direct restoration. 
Two patients presented tongue and labial mucositis and 
were treated with PBM (2J/cm2) once a week. In one pa-
tient, dental trauma in oral mucosa was diagnosed as the 
pain’s cause, and exodontia was undertaken. One patient 
presented BMS that was managed with topical capsai-
cin and benzocaine three times a day. Thermotherapy in 
pain site was recommended for five patients (22,7%).
Systemic pain medication was recommended to fourteen 
patients (63,6%), such as anticonvulsant (45,4%), mus-
cle relaxant (18,1%), nonsteroidal anti-inflammatory 
(9%), common analgesic (4,5%), opioid (4,5%) and an-
tidepressant (4,5%). For two patients (9%) a combina-
tion of two systemic pain drugs was recommended. One 
patient received intramuscular anesthetic (lidocaine 2% 
+ epinephrine 1:100.000) to define the type of pain.
The follow-up ranged from fourteen to 390 days (mean 
95,3 days). Ten patients (45,4%) reported absence of 
pain and six (27,2%) referred mild pain after oral care. 
Three patients (13,6%) maintained severe pain, although 
slightly reduced. One patient reported no response and 
two patients abandoned treatment.
Discussion
The present case series reflects the typical scenario of 
HNC in Brazil, where oral cancer represents the fif-
th commonest malignant neoplasm in men. Tobacco 
smoking and alcohol consumption are the most preva-
lent risk factors, and its diagnostic still remains late in 
the majority of cases (24). In this context, the dentist’s 
role is important to reduce the acute and long-term side 
effects of CRT and surgery for HNC patients. OFP (4), 
trismus (9,22), osteoradionecrosis (16), oral infections 
(25), dysgeusia (9), dental demineralization and caries 
(16,26), mucositis (8), salivary gland hypofunction and 
xerostomia (22) are the most common oral issues that 
affect oncological patient’s quality of life. Poor dental 
health observed in HNC patients is the highest risk fac-
tor for many of these complications and should be pre-
vented with dental prophylactic care and extraction of 
compromised teeth ahead of CRT and surgery (16,27). 
However, the great majority of patients still initiate can-
cer therapy without dental care assessment, a reality 
clearly demonstrated in the present study, where 45,4% 
of our patients presented pain associated with pulpitis 
and only five patients (22,7%) began the OFP manage-
ment and dental treatment before oncological therapy. 
OFP diagnosis is a challenging condition for both den-
tist and physician. General practitioners commonly re-
fer OFP patients to ear, nose and throat, neurology, or 
pain medicine (3), whereas the diagnosis of dental and 
non-dental pain was the basic principle of our proposal. 
According to Epstein et al., clinical presentation of OFP 
depends on cancer stages and its associated therapy. At 
the beginning, pain could be associated with neoplasm 
and its growth or paraneoplastic neuropathy. Perineural 
spread of HNC can give trigeminal neuropathic sympto-
matology in up to 80% of patients (28). This occurs due 
to inflammation within closed spaces that may carry out 
nerve damage secondary to tumor pressure-induced is-
chemia (16). All patients in this study that reported pain 
before cancer therapy were diagnosed with neuropathic 
component, a feature that reinforces this hypothesis. 
Pain during therapy may be associated with neural and 
mucosal damage due to cytotoxicity of CRT or post-sur-
gery anatomical abnormalities (2,27). In this study, 
mucositis was present in two patients that started oral 
treatment during cancer therapy, leading to dysphagia 
and limitation to oral medications intake. Post-surgery 
pain was observed in seven patients (31,8%) with gene-
ral status compromise, and with speech impairment due 
to pain and trismus. Post-surgical pain causes fatigue, 
depression, and impairs quality of life (2). 
The majority of patients in the present study were in 
post-therapy period that is characterized by long-term 
consequences of cancer treatment (2,16). In this group 
we observed radiation caries that is commonly described 
when patients do not receive educative orientations and 
preventive oral care before cancer therapy (16). One pa-
tient of this study complained pain when opening the 
mouth due to sensibility in white spot lesion in cervical 
region of all teeth. 
Definition of OFP’s type based on pathophysiological 
classification is essential to determine its appropriated 
pain management (28). Intermittent nociceptive somatic 
pain was the most frequent type of pain observed in this 
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study, with a variety of sensations. In these cases, the 
pain’s localization was precise (tooth, oral mucosa, and 
musculoskeletal nerve complex) and pain trigger or ag-
gravating factors were obvious. Nociceptive pain’s con-
trol was achieved by complete dental therapy or elimina-
tion of local pain. The results could be demonstrated in 
this study by a decrease in pain score observed at VAS2 
in all patients with nociceptive pain. 
In our series, a mixed-type OFP was diagnosed in some 
cases, with both neuropathic and nociceptive compo-
nents resulting in variable pain characteristics. This 
pain was efficiently treated with analgesic and adjuvants 
drugs, such as nonsteroidal anti-inflammatory, anticon-
vulsant, and antidepressives, associated with removal 
of local causes of pain when it was necessary. Pharma-
cological choice was based on the medical, social, and 
emotional individual history and followed the WHO’s 
analgesic step-up approach (21). 
One patient was diagnosed with BMS secondary to CRT. 
As with other chronic neuropathic pain conditions, BMS 
can be managed by pharmacological or by psychological 
means or by a combination of both (10,29). In this case, 
we proposed a topical capsaicin and systemic anticon-
vulsant, but the patient abandoned treatment, similarly 
to other three cases. 
We decided to report four unconcluded cases to discuss 
the vulnerability of the patients and their families that 
depend on public health service. A Brazilian study (30) 
highlighted some issues that affect this vulnerability in 
the rural population with oral cancer. The knowledge 
about oral cancer, accessibility to dental care, lifestyle 
and socioeconomic status are important factors to take 
into consideration. The majority of patients in our study 
were from rural or suburb areas, and experienced many 
of these difficulties, including limited budget to cover 
the public transportation costs for dental clinic.  
According to Epstein et al., OFP in many cases never 
returns to its baseline status after beginning cancer the-
rapy. These findings were not reproduced in this study 
where pain scores changed from severe or moderate to 
no pain in 45,4% of cases. We believe that our approach 
was successful due to an individual approach and to ca-
reful pain diagnosis and treatment.
There are a limited number of studies assessing OFP in 
HNC patient. Studies addressing the dentist diagnosis 
and management of pain impact in the overall quality of 
life of patients with cancer are needed to improve onco-
logical therapy.
Conclusions
OFP could be associated to tooth, musculoskeletal, and 
some neurological disorders whose diagnosis and treat-
ment depends on the dentist. In this cases report, oral 
care approach enabled pain reduction in 86,3% of pa-
tients, and pain relief was achieved in 45,4% of them. 
Oncological patients should be treated by a multidisci-
plinary team including dentists. 
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